Keywords: ایماتینیب; Imatinib; Intestinal absorption; Intestinal elimination; Active transport; Diffusion chambers
مقالات ISI ایماتینیب (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: ایماتینیب; Chronic myeloid leukaemia; Imatinib; Growth deceleration; Child; Paediatrics;
Keywords: ایماتینیب; Heat pain; Cold pain; c-Kit; Imatinib; Nilotinib; Tactile acuity; Chronic myeloid leukemia; Analgesia; Quantitative sensory testing;
Keywords: ایماتینیب; Imatinib; Mesenchymal stromal cells; Bone remodeling; Chronic myeloid leukemia; Fibrosis;
Keywords: ایماتینیب; Eosinophilia; Chronic eosinophilic leukemia (CEL); Hypereosinophilic syndrome; Systemic mastocytosis; Tryptase; FIP1L1-PDGFRA fusion; Imatinib;
Keywords: ایماتینیب; Chronic myeloid leukemia; Tyrosine kinase inhibitors; Imatinib; Dasatinib; Nilotinib; Bosutinib; Ponatinib;
Keywords: ایماتینیب; Elongation; 3D; Volume; RECIST; Response; Imatinib; GIST; Liver metastases; Morphology; Orientation
Keywords: ایماتینیب; chronic myeloid leukemia; cost-utility analysis; dasatinib; imatinib; leukemia; nilotinib; Thailand;
Keywords: ایماتینیب; Spinal cord injury; BBB scale; Imatinib; Gleevac®; Axon regeneration; Contusion injury; Recovery of function; Bladder function;
Keywords: ایماتینیب; Gastrointestinal stromal tumor; Imatinib; Sarcoma; Oncogenic kinase mutation;
Keywords: ایماتینیب; Gastrointestinal stromal tumour; Surgery; Imatinib;
Keywords: ایماتینیب; Angiogenesis model; Pericyte; Imatinib; Sunitinib; Endoglin; Drug screening; Blood vessel maturation;
Keywords: ایماتینیب; Imatinib; Nilotinib; Chronic myeloid leukemia; Pregnancy;
Keywords: ایماتینیب; imatinib; pharmacokinetic equivalence; pharmacokinetics; bioequivalence;
Keywords: ایماتینیب; Muscular dystrophy; PDGFRα; Satellite cells; Imatinib;
Keywords: ایماتینیب; Tyrosine kinase; Fibrosis; Idiopathic pulmonary fibrosis; Systemic sclerosis; Imatinib; Intedanib;
Keywords: ایماتینیب; Gastrointestinal stromal tumours; Imatinib; Patient selection; Mutational analysis; Sarcoma;
Keywords: ایماتینیب; Chronic myeloid leukemia; Imatinib; Nilotinib; Dasatinib; Drug resistance; Adverse drug event;
Keywords: ایماتینیب; chronic myeloid leukemia; complete cytogenetic response; dasatinib; health technology assessment; HTA; imatinib; intermediate outcomes; major molecular response; nilotinib; surrogate end points; systematic review; technology appraisal;
Keywords: ایماتینیب; Drug reimbursement; Systematic review; Evidence development; Imatinib; Pegfilgrastim; Adalimumab;
Keywords: ایماتینیب; Tumor interstitial fluid pressure; Intratumoral delivery; Combination therapy; Imatinib; Doxorubicin; Sterically stabilized liposome;
Keywords: ایماتینیب; Imatinib; Chronic myeloid leukemia; Hair analysis; Liquid chromatography–mass spectrometry; Therapeutic drug monitoring; Adherence evaluation
Keywords: ایماتینیب; Atherosclerosis; Cholesterol; Imatinib; Macrophages
Keywords: ایماتینیب; Dasatinib; Imatinib; Nilotinib; Optic neuropathy; Chronic myeloid leukemia; Visual campimetry/perimetry
Carving out another slice of the pie: Exceptional response to single agent imatinib in an asian female never-smoker with advanced NSCLC with a de-novo PDGFR-α N848âK mutation
Keywords: ایماتینیب; NSCLC; PDGFRA; Imatinib; Driver mutation; Precision medicine;
Identification of chronic myeloid leukemia patients treated with imatinib who are potentially eligible for treatment discontinuation by assessing real-life molecular responses on the international scale in a EUTOS-certified lab
Keywords: ایماتینیب; CML; chronic myeloid leukemia; CML-CP; chronic myeloid leukemia in chronic phase; DMR; deep molecular response; ELN; European LeukemiaNet; ENESTFreedom; Evaluating Nilotinib Efficacy and Safety in Clinical Trials - Following REsponsE in De nOvo CML-CP P
Vogt-Koyanagi-Harada disease like presentation in patients with chronic myeloid leukemia
Keywords: ایماتینیب; Chronic myeloid leukemia; Panuveitis; Vogt-Koyanagi-Harada disease; Tyrosine kinase inhibitors; Dasatinib; Imatinib;
Outcome of Chronic Myeloid Leukemia-Chronic Phase Patients Treated With Imatinib: A Local Experience
Keywords: ایماتینیب; Imatinib; Philadelphia chromosome; Retrospective; Saudi; TKI;
Treatment outcomes in older patients with advanced gastrointestinal stromal tumor (GIST)
Keywords: ایماتینیب; Gastrointestinal stromal tumor; Imatinib; Sunitinib; Prognosis; Older age;
Sclerodermatous Chronic Graft-versus-Host Disease Treated With Imatinib: A Dermatological Perspective
Keywords: ایماتینیب; Graft-versus-host disease; Chronic sclerodermatous graft versus host disease; Cutaneous graft versus host disease; Imatinib; Treatment; Platelet-derived growth factor receptor; Enfermedad de injerto contra huésped; Enfermedad de injerto contra huésped c
Effect of ABCG2, OCT1, and ABCB1 (MDR1) Gene Expression on Treatment-Free Remission in a EURO-SKI Subtrial
Keywords: ایماتینیب; ABCG2; Biomarker; CML; Imatinib; Prediction;
BCL2 inhibitor ABT-199 and JNK inhibitor SP600125 exhibit synergistic cytotoxicity against imatinib-resistant Ph+ ALL cells
Keywords: ایماتینیب; ABL; Abelson kinase; ALL; acute lymphoblastic leukemia; BCR; break clustering region; CML; chronic myeloid leukemia; DST; dasatinib; IMT; imatinib; NRT; nirotinib; Ph+; Philadelphia chromosome positive; TKI; tyrosine kinase inhibitor; Ph+ ALL; Imatinib-re
Platelet-derived growth factor receptor alpha (PDGFRα) is overexpressed in NK/T-cell lymphoma and mediates cell survival
Keywords: ایماتینیب; PDGFRα; NK/T-cell lymphoma; Imatinib;
Exosomes from mesenchymal stromal cells enhance imatinib-induced apoptosis in human leukemia cells via activation of caspase signaling pathway
Keywords: ایماتینیب; apoptosis; caspase; exosome; imatinib; mesenchymal stromal cells;
Impact of SLC22A1 and CYP3A5 genotypes on imatinib response in chronic myeloid leukemia: A systematic review and meta-analysis
Keywords: ایماتینیب; Chronic myeloid leukemia; Imatinib; Meta-analysis; SLC22A1; CYP3A5; Polymorphisms;
HDAC inhibitor suppresses proliferation and tumorigenicity of drug-resistant chronic myeloid leukemia stem cells through regulation of hsa-miR-196a targeting BCR/ABL1
Keywords: ایماتینیب; Chronic myeloid leukemia; Myelogenous leukemia; Hematopoietic stem cells; HDAC inhibition; SAHA; Imatinib; hsa-miR-196a; Chemoresistance;
Synergistic activity of imatinib and AR-42 against chronic myeloid leukemia cells mainly through HDAC1 inhibition
Keywords: ایماتینیب; Chronic myeloid leukemia; Combination therapy; Imatinib; AR-42; HDAC1;
Cytotoxic activity of fucoxanthin, alone and in combination with the cancer drugs imatinib and doxorubicin, in CML cell lines
Keywords: ایماتینیب; Antiproliferation; CML; Doxorubicin; Fucoxanthin; Imatinib;
Pharmacological inhibition of JAK3 enhances the antitumor activity of imatinib in human chronic myeloid leukemia
Keywords: ایماتینیب; Chronic myeloid leukemia; JAK inhibitor; BCR-ABL; Tofacitinib; Imatinib;
Anodic oxidation of anti-cancer drug Imatinib on different electrodes: Kinetics, transformation by-products and toxicity assessment
Keywords: ایماتینیب; Anodic oxidation; Imatinib; By-products; Toxicity; BDD; MMO electrodes;
Early clinical observations on the use of imatinib mesylate in FOP: A report of seven cases
Keywords: ایماتینیب; Fibrodysplasia ossificans progressiva (FOP); Heterotopic ossification; Imatinib; Bone morphogenetic protein (BMP) signaling; HIF1-α; ACVR1; PDGFRα; c-Kit;
Eco-friendly intracellular microalgae synthesis of fluorescent CdSe QDs as a sensitive nanoprobe for determination of imatinib
Keywords: ایماتینیب; Microalgae cells; Biosynthesized CdSe QDs; Fluorescent probe; Imatinib; Detection;
Comparison of Frequency and Sensitivity of BCR-ABL1 Kinase Domain Mutations in Asian and White Patients With Imatinib-resistant Chronic-Phase Chronic Myeloid Leukemia
Keywords: ایماتینیب; Asian countries; BCR-ABL1 mutation; CML; Drug resistance; Imatinib;
Bioinspired co-crystals of Imatinib providing enhanced kinetic solubility
Keywords: ایماتینیب; Co-crystals; Imatinib; Syringic acid; Solubility; Permeation; Aggregation; Supersaturation;
Regulatory T cell-targeted hybrid nanoparticles combined with immuno-checkpoint blockage for cancer immunotherapy
Keywords: ایماتینیب; Cancer immunotherapy; CTLA-4; Hybrid nanoparticles; Imatinib; tLyp1 peptide; Treg cell;
Imatinib prevents lung cancer metastasis by inhibiting M2-like polarization of macrophages
Keywords: ایماتینیب; TAM; tumor associated macrophage; CD206; cluster of differentiation 206; BMDMs; bone marrow derived macrophages; Arg1; arginase 1; Mgl2; macrophage galactose N-acetyl-galactosamine specific lectin 2; Mrc1; mannose receptor C-type 1; CDH1; cadherin 1; CCL2
Co-delivery of doxorubicin and imatinib by pH sensitive cleavable PEGylated nanoliposomes with folate-mediated targeting to overcome multidrug resistance
Keywords: ایماتینیب; Doxorubicin; Imatinib; Drug resistance; pH-sensitive; Liposomes;
Oncogenic Kit signalling on the Golgi is suppressed by blocking secretory trafficking with M-COPA in gastrointestinal stromal tumours
Keywords: ایماتینیب; GIST; Kit tyrosine kinase; Imatinib; Golgi apparatus; M-COPA; BFA; brefeldin A; ER; endoplasmic reticulum; GIST; gastrointestinal stromal tumour; M-COPA; 2-methylcoprophilinamide; mut; mutant; PDGFRA; platelet-derived growth factor receptor A; PI3K; phosp
IL-7-induced phosphorylation of the adaptor Crk-like and other targets
Keywords: ایماتینیب; Interleukin 7; Apoptosis; Tyrosine phosphorylation; Crk-like; Imatinib; LAIR1;
Targeting heme Oxygenase-1 with hybrid compounds to overcome Imatinib resistance in chronic myeloid leukemia cell lines
Keywords: ایماتینیب; HO-1 inhibitors; Tyrosine kinase inhibitors; BCR-ABL; Imatinib; Chronic myeloid leukemia;